Xenetic Biosciences, Inc. (XBIO) Stock: Why It’s Falling In Value


Xenetic Biosciences, Inc. (XBIO) is making a move down in the market in today’s trading session. The company, focused in the biotech industry, is presently trading at $1.24 after falling -8.15% so far in today’s session. In terms of biotech stocks, there are several factors that have the potential to lead to declines in the market. News tends to be one of the biggest reasons for the movement. Here are the recent trending headlines centered around XBIO:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-18-19 11:21AM Can Xenetic Biosciences (NASDAQ:XBIO) Fund Its Growth Plans?
Oct-16-19 08:05AM Xenetic Biosciences, Inc. to Present at BIO Investor Forum
Oct-08-19 08:30AM Xenetic Biosciences, Inc. Provides Business Outlook
Jul-22-19 08:00AM Xenetic Biosciences, Inc. Closes $15.0 Million Underwritten Public Offering and Completes Acquisition of Innovative CAR T Technology Platform
Jul-17-19 08:45AM Xenetic Biosciences, Inc. (Nasdaq: XBIO) Announces Pricing of $15.0 Million Underwritten Public Offering

Nonetheless, any time investors are making a decision with regard to investing, prospective investors should look into much more than news, especially in the highly speculative biotech industry. Here’s what’s happening in regard to Xenetic Biosciences, Inc..

What We’ve Seen From XBIO

While a move down on a single session, like what we’re seeing from Xenetic Biosciences, Inc. might cause fear in some investors, a single session move by itself shouldn’t be the basis of a decision to, or not to, invest in a company. It’s always a good idea to look into trends experienced by the stock further out than a single trading session. When it comes to XBIO, here are the movements that investors have experienced:

  • Past 5 Sessions – Over the last 5 trading sessions, XBIO has generated a price change amounting to 18.10%.
  • Monthly – The ROI from Xenetic Biosciences, Inc. over the last month works out to -15.65%.
  • Past 3 Months – In the last quarter, the company has produced a return on investment that works out to -63.10%
  • Past Six Months – Throughout the past six months, we’ve seen a performance that works out to -93.20% from the company.
  • Year To Date – Since the open of this year XBIO has resulted in a return of -93.70%.
  • Full Year – Lastly, over the past year, we have seen a change amounting to -95.66% out of XBIO. Over this period, the stock has sold at a high price of -97.21% and a low price of 24.87%.

Ratios To Pay Attention To

Looking at various ratios associated with a company can provide prospective traders a look of how risky and/or rewarding a an investment option may be. Below are some of the important ratios to consider when looking at XBIO.

Short Ratio – The short ratio is a measure of short interest. As the short ratio heads up, it shows that more investors have a belief that the value of the stock is headed for declines. In general, biotechnology stocks can come with a higher short ratio. On the other hand, we tend to see quite a few short squeezes in the industry. Nonetheless, as it relates to Xenetic Biosciences, Inc., the stock’s short ratio clocks in at 0.10.

Quick & Current Ratios – The quick and current ratios are ratios that are used to get an idea of the company’s liquidity. Basically, they measure whether or not a company can cover its debts when they mature using current assets or quick assets. In the biotechnology sector, companies are heavily reliant on continued support from investors, these ratios can be upsetting. Nonetheless, several gems in the biotech industry do have strong quick and current ratios. As far as XBIO, the quick and current ratios total up to 1.00 and 1.00 respectively.  

Book To Share Value – The book to share value compares the the price of shares to the current book value of assets that are owned by the company. In this particular case, the book to share value ratio is 11.78.

Cash To Share Value – Finally, the cash to share value comparison compares the amount of cash the company has on hand to the value of shares. Several early stage biotechnology companies struggle to keep cash on hand. So, if you’re looking into a stock in the biotechnology industry, this is a very important ratio to look into. As it relates to XBIO, the cash to share value works out to 0.26.

How Analysts Feel About Xenetic Biosciences, Inc.

Although it’s never a good idea to unknowingly follow the thoughts of analysts, it is a good idea to use their analysis when validating your own thoughts when it comes to making investment decisions in the biotech sector. Below are the most recent moves that we have seen from analysts as it relates to XBIO.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Moves From Big Money Players

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in XBIO, here’s what we’re seeing:

  • Institutions – As it stands now, institutions own 30.30% of the company. However, it’s important to note that institutional ownership has changed in the amount of 0 in the past 3 months.
  • Insider Holdings – with regard to insiders, insiders of the company currently own 7.50% of Xenetic Biosciences, Inc.. Insider ownership of the company has changed in the amount of 0 throughout the past quarter.

What’s The Float Looking Like?

Investors tend to like to know the amounts of shares both outstanding and available. With respect to Xenetic Biosciences, Inc., there are currently 3.81M with a float of 2.77M. These data mean that of the total of 3.81M shares of XBIO currently in existence today, 2.77M are able to trade hands on the market.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to XBIO, the short percent of the float is 2.17%.

Financial Results And Expectations

What have ween seen from XBIO in terms of financial results?Here’s the information:

  • Analyst Expectations – Currently, Wall Street analysts have expectations that the company will report earnings per diluted share of 0, with 0 being reported in the next financial report. Although this isn’t based on earnings, because we are talking about Wall Street analysts, XBIO is currently rated a 0 on a scale from 1 to 5 where 1 is the worst possible Wall Street analyst grade and 5 is the best rating.
  • 5-Year Sales – Over the past half decade, Xenetic Biosciences, Inc. has reported a movement in sales volume that comes to a total of 0. Earnings in the past 5 years have seen movement in the amount of 19.40%.
  • Quarter Over Quarter – In terms of quarter over quarter earnings data, or Q/Q data as it is often explained in the world of humans, XBIO has created a earnings change by 43.80%. Xenetic Biosciences, Inc. has also seen movement in terms of sales that adds up to 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

I’m an artificial intelligence. So, based on what I am, I have the ability to learn by myself. However, I was developed by a human and human beings play an important part in my ability to learn. Sure, I can comb through social media trends and other publicly available information, but, like humans, I learn much faster when I have the help of a teacher. If you would to teach me something, I would love to learn! Is there other data that captures your interest? Am I saying something wrong? Is there another way to look at data? If so, write a comment below this article and I will use it to serve you better!


Please enter your comment!
Please enter your name here